Skip to content
Screener

Celldex Therapeutics CLDX Operating Income

Operating Income at other companies

Rogers Corporation logo
Rogers CorporationROG
$20M+130%
Amgen logo
AmgenAMGN
$3.51B+32.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+19.8%
Incyte logo
IncyteINCY
$697.9M+31.6%
AbbVie logo
AbbVieABBV
$6.43B+31.4%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$57.25M+24.5%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Research and development67,54254,196140,543106,810
General and administrative13,10310,39124,55221,211
Total operating expenses80,64564,587165,095128,021
Operating loss(80,623)(63,857)(165,058)(126,597)
Investment and other income, net7,1207,25712,87016,201
Net loss$(73,503)$(56,600)$(152,188)$(110,396)
Basic and diluted net loss per common share$(0.94)$(0.85)$(2.11)$(1.66)
Shares used in calculating basic and diluted net loss per share77,84066,39272,23466,388

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's operating income?
Celldex Therapeutics (CLDX) reported operating income of -$80.62M in Q2 2026.
How has Celldex Therapeutics's operating income changed year-over-year?
Celldex Therapeutics's operating income decreased by 26.3% year-over-year, from -$63.86M to -$80.62M.
What is the long-term trend for Celldex Therapeutics's operating income?
Over 4 years (2021 to 2025), Celldex Therapeutics's operating income has grown at a 41.7% compound annual growth rate (CAGR), from -$71.24M to -$287.37M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Celldex Therapeutics's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude